Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

Author： Hortobagyi Gabriel   Gomez Henry   Li Rubi   Chung Hyun-Cheol   Fein Luis   Chan Valorie   Jassem Jacek   Lerzo Guillermo   Pivot Xavier   Hurtado de Mendoza Fernando   Xu Binghe   Vahdat Linda   Peck Ronald   Mukhopadhyay Pralay   Roché Henri  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.122, Iss.2, 2010-07, pp. : 409-418

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

By Roché Henri  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 755-765

Springer Publishing Company

Access to resources Recommend Favorite

Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer

By Li Lun   Li Jiang   Yang Kehu   Tian Jinhui   Sun Tiantian   Jia Wenqin   Zhang Peng   Yi Kang  

Future Oncology, Vol. 6, Iss. 2, 2010-02 ,pp. : 201-207

Future Medicine

Access to resources Recommend Favorite

Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy

By Clemons Mark   Joy Anil   Abdulnabi Radhi   Kotliar Mauricio   Lynch Jodi   Jordaan Johan   Iscoe Neill   Gelmon Karen  

Breast Cancer Research and Treatment, Vol. 124, Iss. 1, 2010-11 ,pp. : 177-186

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer

By Song Hong   Do Young   Chang Heung   Ryu Min   Lee Kyung   Kim Yeul   Hong Dae   Cho Jae   Lee Kyoung   Kim Si  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 5, 2008-10 ,pp. : 763-768

Springer Publishing Company

Access to resources Recommend Favorite

Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study

By Santini Daniele   Vincenzi Bruno   Schiavon Gaia   Di Seri Marisa   Virzí Vladimir   Spalletta Bruno   Caricato Marco   Coppola Roberto   Tonini Giuseppe  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 613-620

Springer Publishing Company

Access to resources Recommend Favorite